DelistingJun 1, 2026, 07:32 AM
HCW Biologics Gets Nasdaq Extension; Must Regain $1 Bid Price by July 29
AI Summary
HCW Biologics Inc. has been granted an extension by the Nasdaq Hearings Panel to regain compliance with the minimum $1 bid price rule. The company must achieve a bid price of $1 or more for 20 consecutive trading days by July 29, 2026. This extension comes after the company failed to meet the bid price requirement and was not given a standard 180-day grace period due to a prior reverse stock split. The Panel has imposed strict conditions, including immediate delisting for any further bid price deficiency before September 22, 2026.
Key Highlights
- HCW Biologics received a notice on March 26, 2026, for failing to maintain a minimum bid price of $1 per share for 30 consecutive business days.
- The company was not afforded a 180-calendar day period due to a 1-for-40 reverse stock split on April 11, 2025.
- Nasdaq Hearings Panel granted an extension on May 29, 2026, following a hearing on May 5, 2026.
- HCW Biologics must demonstrate compliance with the $1 bid price rule by July 29, 2026, for 20 consecutive trading days.
- Immediate delisting will occur if the company becomes deficient with the Bid Price Rule prior to September 22, 2026.
- If other listing rules are violated before September 22, 2026, the company has seven days to present a cure plan.
- A Discretionary Panel Monitor will be imposed for an additional one-year period if compliance is regained.
Price Impact
More from HCWB